Join visiting researcher Dr Paul Liknaitzky, alongside Dr Rob Schutze & Dr Jeremy Tannenbaum, for an evening dedicated to understanding the principles, potentials and pitfalls of Psychedelic science and therapies. The evening begins with a guest lecture from visiting researcher, Dr Paul Liknaitzky, PhD, Head of the Clinical Psychedelic Lab at Monash University, followed by short talks from Dr Rob Schutze and Dr Jeremy Tannenbaum. Following presentations will be a moderated panel discussion.
Speakers
- Visiting Researcher Dr Paul Liknaitzky PhD
Head, Monash Clinical Psychedelics Lab - Dr Jeremy Tannenbaum
Pain Medicine Specialist, Physician and Psychiatrist - Dr Rob Schutze PhD
Clinical Psychologist & Curtin researcher
Psychedelic Science and Therapies: Principles, Potentials, Pitfalls
Psychedelic therapies are making a comeback, with rapid increases in research programs, financial investment, and public interest. The Australian TGA will permit service delivery of MDMA and psilocybin for certain conditions from 1st July 2023. However, the capacity to deliver this unique class of treatments and the availability of adequate training, infrastructure, and standards of care are limited. Healthcare practitioners increasingly ask about the key principles and best practice in psychedelic therapies, what the research to date suggests, what the risks might be within service delivery, and what the initial stages of regulated psychedelic therapy might look like. And people in the general public increasingly ask about safety and effectiveness, what psychedelic treatments are like, and how they would discern suitability in a provider. This talk aims to address these questions.
About Paul Liknaitzky
Paul Liknaitzky is Head of Clinical Psychedelic Research at Monash University, and Chief Principal Investigator on a program of psychedelic trials. He is a Research Fellow within both the Dept of Psychiatry and the Turner Institute at Monash University, and earned an Honours in Neuroscience and a PhD in Psychology from the University of Melbourne. In Australia, he is an Investigator on several of the country’s initial psychedelic trials, has coordinated a number of psychedelic therapist training and supervision programs, and leads the first clinical psychedelic lab. His work is focused on developing a rigorous program of research in clinical psychedelics that seeks to innovate on treatment design, evaluate therapeutic effects, mitigate known risks, explore potential drawbacks, and understand therapeutic mechanisms.
